Grant ID RP180166
Awarded On February 21, 2018
Title Molecular mechanisms of anthracycline response in cardiomyocytes and link to genetic susceptibility to cardiotoxicity in long-term childhood cancer survivors
Program Academic Research
Award Mechanism Individual Investigator Research Awards for Cancer in Children and Adolescents
Institution/Organization The University of Texas M.D. Anderson Cancer Center
Principal Investigator/Program Director Michelle Hildebrandt
Cancer Sites All Sites
Contracted Amount $1,194,520
Lay Summary

Anthracyclines are highly effective chemotherapeutic drugs that improve survival for many types of childhood cancers, but are known to cause irreversible and progressive cardiac damage that often manifests decades following treatment. These late cardiotoxic effects are a serious complication of cancer treatment and are the third most common cause of premature death in long-term survivors of childhood cancer. The underlying mechanisms for the development of late cardiotoxicity remain unclear due to lack of human model systems to explore the effect of anthracyclines on the cardiomyocyte. With the emergence of pluripotent stem cell (iPSC)-derived cardiomyocytes as a model system, this study was...

Read More